Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1346701 | 0.89 | PTPN1 (0.48) | SCN9APTPN1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1346972 | 0.89 | SCN9A (0.43) | SCN9APTPN1SLC6A4MAOB | |
| SCHEMBL1346734 | 0.89 | S1PR5 (0.49) | SCN9AS1PR5S1PR1SLC6A4SLC6A2 | |
| SCHEMBL1346572 | 0.88 | NPC1 (0.45) | SCN9APTPN1SLC6A4MAOB | |
| SCHEMBL1346576 | 0.84 | SCN9A (0.49) | SCN9APTPN1MAOB | |
| SCHEMBL1347251 | 0.84 | SLC6A4 (0.52) | SCN9AS1PR5S1PR1SLC6A4SLC6A2 | |
| SCHEMBL1344906 | 0.83 | GPR52 (0.40) | SCN9ASLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL1346343 | 0.82 | HTT (0.46) | SCN9AMAOB | |
| SCHEMBL1346346 | 0.82 | SCN9A (0.44) | SCN9AMAOBF10 | |
| SCHEMBL1346610 | 0.82 | SCN9A (0.44) | SCN9AMAOBF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063039-B2 | 3-aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-11-22 | — | — | US | claimed |
| US-20100048665-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A., (IT) | 2010-02-25 | — | — | US | claimed |
| EP-1685103-B1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARM SPA (IT) | 2008-07-30 | — | — | EP | claimed |
| US-20070135410-A1 | 3-Aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | claimed |
| CN-1882536-A | 3-aminopyrrolidone derivatives | NEWRON PHARM SPA (IT) | 2006-12-20 | — | — | CN | claimed |
| EP-1533298-A1 | 3-aminopyrrolidone derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-05-25 | — | — | EP | claimed |
| US-8063039-B2 | 3-aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-11-22 | — | — | US | disclosed |
| US-7968592-B2 | 3-aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| US-20100048665-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A., (IT) | 2010-02-25 | — | — | US | disclosed |
| EP-1685103-B1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARM SPA (IT) | 2008-07-30 | — | — | EP | disclosed |
| US-20070135410-A1 | 3-Aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | disclosed |
| CN-1882536-A | 3-aminopyrrolidone derivatives | NEWRON PHARM SPA (IT) | 2006-12-20 | — | — | CN | disclosed |
| EP-1533298-A1 | 3-aminopyrrolidone derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135410-A1 | 3-Aminopyrrolidone derivatives | TRPC3, TRPV3, CACNA1D | SCN9A 690/4885S1PR5 1466/4885S1PR1 1661/4885 |
| US-20100048665-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | TRPC3, TRPV3, CACNA1D | SCN9A 690/4885S1PR5 1466/4885S1PR1 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.